Overview

Eribulin Plus Tucidinostat in the Treatment of HER2-negative Advanced Breast Cancer

Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Study to Evaluate the Safety and Efficacy of Eribulin plus Tucidinostat in the Treatment of HER2-negative Advanced Breast Cancer
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Henan Cancer Hospital